Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of CNS penetrant therapeutics.
Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (“Tenacia”), a commercial-stage biopharmaceutical ...